MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab Oct. 19, 2007 By Donna Young MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today)Read More
International report: Para-diagnostic devices from two firms boost retail trade Oct. 18, 2007 By John Brosky
RSS